IRIS Institutional Research Information System - OPENBS Open Archive UniBS

ODICINO, Franco Edoardo
 Distribuzione geografica
Salva come PNG Salva come JPEG
Continente #
NA - Nord America 10.263
EU - Europa 5.840
AS - Asia 5.462
SA - Sud America 882
AF - Africa 160
OC - Oceania 73
Continente sconosciuto - Info sul continente non disponibili 6
AN - Antartide 1
Totale 22.687
Salva come PNG Salva come JPEG
Nazione #
US - Stati Uniti d'America 9.993
IT - Italia 2.318
SG - Singapore 1.865
CN - Cina 1.521
BR - Brasile 727
UA - Ucraina 654
HK - Hong Kong 593
DE - Germania 506
PL - Polonia 501
GB - Regno Unito 351
BD - Bangladesh 322
VN - Vietnam 318
FI - Finlandia 306
FR - Francia 265
TR - Turchia 211
RU - Federazione Russa 191
IN - India 186
CA - Canada 156
IE - Irlanda 151
CH - Svizzera 146
ES - Italia 90
ID - Indonesia 85
SE - Svezia 68
NL - Olanda 66
MX - Messico 64
AU - Australia 60
AR - Argentina 59
JP - Giappone 58
IQ - Iraq 56
ZA - Sudafrica 53
EE - Estonia 49
SA - Arabia Saudita 42
MY - Malesia 23
EC - Ecuador 22
AT - Austria 21
LT - Lituania 19
MA - Marocco 19
PH - Filippine 19
UZ - Uzbekistan 19
PK - Pakistan 18
CZ - Repubblica Ceca 17
CL - Cile 16
BE - Belgio 15
PE - Perù 15
PT - Portogallo 15
JO - Giordania 14
AE - Emirati Arabi Uniti 13
EG - Egitto 13
KE - Kenya 13
LI - Liechtenstein 13
VE - Venezuela 13
DZ - Algeria 11
JM - Giamaica 11
NP - Nepal 11
NZ - Nuova Zelanda 11
AZ - Azerbaigian 10
CO - Colombia 10
LU - Lussemburgo 10
BG - Bulgaria 9
CR - Costa Rica 9
IL - Israele 9
SK - Slovacchia (Repubblica Slovacca) 9
TN - Tunisia 9
BO - Bolivia 8
KR - Corea 8
KZ - Kazakistan 8
AL - Albania 7
DK - Danimarca 7
ET - Etiopia 7
MK - Macedonia 7
PY - Paraguay 7
BH - Bahrain 6
IR - Iran 6
NG - Nigeria 6
OM - Oman 6
TH - Thailandia 6
UG - Uganda 6
EU - Europa 5
GH - Ghana 5
GR - Grecia 5
HN - Honduras 5
KG - Kirghizistan 5
UY - Uruguay 5
GT - Guatemala 4
LK - Sri Lanka 4
MU - Mauritius 4
NI - Nicaragua 4
PS - Palestinian Territory 4
RO - Romania 4
RS - Serbia 4
BS - Bahamas 3
BY - Bielorussia 3
CI - Costa d'Avorio 3
IS - Islanda 3
LV - Lettonia 3
TT - Trinidad e Tobago 3
TW - Taiwan 3
AM - Armenia 2
BB - Barbados 2
CM - Camerun 2
Totale 22.647
Salva come PNG Salva come JPEG
Città #
Ashburn 1.061
Singapore 952
Fairfield 913
Woodbridge 768
Hong Kong 585
San Jose 502
Houston 490
Warsaw 485
Jacksonville 445
Seattle 385
Wilmington 384
New York 378
Chandler 344
Beijing 340
Ann Arbor 338
Cambridge 327
Los Angeles 253
The Dalles 253
Princeton 239
Milan 204
Helsinki 172
Dearborn 169
Brescia 166
Nanjing 158
Lauterbourg 150
Dublin 147
Istanbul 141
Munich 127
Ho Chi Minh City 115
Council Bluffs 108
Dallas 105
London 101
Des Moines 100
Rome 96
Chicago 91
Moscow 90
Zurich 90
Buffalo 88
São Paulo 75
Santa Clara 74
San Francisco 72
Redondo Beach 69
Shanghai 66
Hanoi 63
Boardman 61
Shenyang 51
Toronto 51
Nanchang 49
Tallinn 49
Jakarta 48
Changsha 43
Orem 43
Hangzhou 42
Frankfurt am Main 41
San Diego 41
Hebei 40
Chennai 38
Tokyo 37
Denver 36
Montreal 36
Tianjin 36
Stockholm 34
Turku 33
Jinan 32
Johannesburg 31
Charlotte 30
Guangzhou 29
Jiaxing 29
Nuremberg 29
Poplar 28
Brooklyn 27
Melbourne 27
Turin 26
Kunming 25
Paris 24
Dhaka 22
Romola 22
Boston 21
Mexico City 21
Naples 21
Dong Ket 20
Lappeenranta 20
Phoenix 20
Pune 20
Washington 20
Ankara 18
Baghdad 18
Belo Horizonte 18
Manchester 18
Atlanta 17
Mumbai 17
Verona 17
Pleasanton 16
Amsterdam 15
Bologna 15
Brasília 15
Genoa 15
Hefei 15
Orange 15
Zhengzhou 15
Totale 13.876
Salva come PNG Salva come JPEG
Nome #
Timing of surgery following SARS-CoV-2 infection: an international prospective cohort study 2.772
Preeclampsia and late fetal growth restriction 397
Identification of stably expressed reference small non-coding RNAs for microRNA quantification in high-grade serous ovarian carcinoma tissues 361
Diagnostic and prognostic impact of serum HE4 detection in endometrial carcinoma patients. 331
Claudin3 is localized outside the tight junctions in human carcinomas 293
Evaluation of a novel human IgG1 anti-claudin3 antibody that specifically recognizes its aberrantly localized antigen in ovarian cancer cells and that is suitable for selective drug delivery 286
Correlation between serological immune response analyzed by a new ELISA for HPV-16/18 E7 oncoprotein and clinical characteristics of cervical cancer patients. 219
Circulating miRNA landscape identifies miR-1246 as promising diagnostic biomarker in high-grade serous ovarian carcinoma: A validation across two independent cohorts 211
Differential gene expression profiles between tumor biopsies and short-term primary cultures of ovarian serous carcinomas: identification of novel molecular biomarkers for early diagnosis and therapy. 204
FOXM1 expression is significantly associated with chemotherapy resistance and adverse prognosis in non-serous epithelial ovarian cancer patients 202
Trop-2 overexpression as an independent marker for poor overall survival in ovarian carcinoma patients. 188
Abridged republication of FIGO's staging classification for cancer of the ovary, fallopian tube, and peritoneum 187
RERT: A Novel Regression Tree Approach to Predict Extrauterine Disease in Endometrial Carcinoma Patients 180
Role of 18F-FDG PET/CT in restaging and follow-up of patients with uterine sarcomas 178
Mammaglobin B is an independent prognostic marker in epithelial ovarian cancer and its expression is associated with reduced risk of disease recurrence 177
Female Adnexal Tumor of Probable Wolffian Origin (FATWO): Case Report and Systematic Literature Review 176
Serum human epididymis protein 4 and risk for ovarian malignancy algorithm as new diagnostic and prognostic tools for epithelial ovarian cancer management. 176
Abridged republication of FIGO's staging classification for cancer of the ovary, fallopian tube, and peritoneum 176
MAL gene overexpression as a marker of high-grade serous ovarian carcinoma stem-like cells that predicts chemoresistance and poor prognosis 174
Mutational landscape of uterine and ovarian carcinosarcomas implicates histone genes in epithelial-mesenchymal transition 173
Trefoil factor 3: a novel serum marker identified by gene expression profiling in highgrade endometrial carcinomas 168
Consolidation therapies revisited: weekly paclitaxel 168
Carcinoma of the Fallopian tube 163
Clinical and prognostic value of 18 F-FDG PET/CT in recurrent endometrial carcinoma 162
Activity of chemotherapy in mucinous ovarian cancer with a recurrence free interval of more than 6 months: results from the SOCRATES retrospective study 159
Human epididymis protein 4 as a serum marker for diagnosis of endometrial carcinoma and prediction of clinical outcome 153
Carcinoma of the corpus uteri 152
Carcinoma of the Fallopian tube 150
The HIV-protease inhibitor saquinavir reduces proliferation, invasion and clonogenicity in cervical cancer cell lines 150
Treatment of Early Cesarean Scar Pregnancy with Double Balloon Catheter: A Systematic Review of the Literature 149
Kinase-driven metabolic signalling as a predictor of response to carboplatin-paclitaxel adjuvant treatment in advanced ovarian cancers 147
Claudin 7 downregulation is predictive of distant metastasis in high-grade serous carcinoma patients 146
Role of HPV DNA, HPV mRNA and cytology in the follow-up of women treated for cervical dysplasia. 146
Adjuvant cisplatin-based chemotherapy for stage I and II ovarian cancer: a 7-year experience 145
Improved Risk Prediction in Human Papillomavirus-Associated Endocervical Adenocarcinoma Through Assessment of Binary Silva Pattern-based Classification: An International Multicenter Retrospective Observational Study Led by the International Society of Gynecological Pathologists (ISGyP) 142
Early stage ovarian cancer: the Italian contribution to clinical research. An update 142
Parametrial endometriosis with ureteral involvement: A case report of a conservative approach without ureteral resection 142
Pattern of failure and value of follow-up procedures in endometrial and cervical cancer patients. 141
Replacement therapy for breast cancer survivors. A pilot study 141
Expression profiles of PRKG1, SDF2L1 and PPP1R12A are predictive and prognostic factors for therapy response and survival in high-grade serous ovarian cancer 141
Polymerase ε (POLE) ultra-mutation in uterine tumors correlates with T lymphocyte infiltration and increased resistance to platinum-based chemotherapy in vitro 140
Staging classification for cancer of the ovary, fallopian tube, and peritoneum 138
A prognostic model for use before elective surgery to estimate the risk of postoperative pulmonary complications (GSU-Pulmonary Score): a development and validation study in three international cohorts 137
Carcinoma of the corpus uteri. FIGO 6th Annual Report on the Results of Treatment in Gynecological Cancer. 137
LncRNAs as novel indicators of patients' prognosis in stage i epithelial ovarian cancer: A retrospective and multicentric study 137
New development of the FIGO staging system. 135
Carcinoma of the fallopian tube. FIGO 6th Annual Report on the Results of Treatment in Gynecological Cancer. 135
Interval debulking surgery in advanced epithelial ovarian cancer 135
Poor outcome of elderly patients with platinum-sensitive recurrent ovarian cancer: results from the SOCRATES retrospective study 134
Carcinoma of the corpus uteri 134
Prognosis of papillary serous, clear cell, and grade 3 stage I carcinoma of the endometrium 134
Gestational trophoblastic diseases 134
Results of the 2006 Innsbruck International Consensus Conference on intraperitoneal chemotherapy in patients with ovarian cancer 134
Carcinoma of the ovary. FIGO 6th Annual Report on the Results of Treatment in Gynecological Cancer. 133
Low Expression of Claudin-7 as Potential Predictor of Distant Metastases in High-Grade Serous Ovarian Carcinoma Patients 133
null 132
Death following pulmonary complications of surgery before and during the SARS-CoV-2 pandemic 132
Morphologic and biologic studies on ten cases of verrucous carcinoma of the vulva supporting the theory of a discrete clinico-pathologic entity 131
Five-year follow-up of placental involution after abdominal pregnancy 130
The claudin-low subtype of high-grade serous ovarian carcinoma exhibits stem cell features 130
History of the FIGO cancer staging system 129
Management of endometrial cancer in Italy: a national survey endorsed by the Italian Society of Gynecologic Oncology 128
Systemic therapy for gynecological neoplasms: ovary, cervix and endometrium 127
Carcinoma of the cervix uteri 127
Gestational trophoblastic diseases 126
Ultrasound examination in ovarian cancer patients. A comparison with second look laparotomy 125
Hormone replacement therapy in breast cancer 125
Systemic therapy for gynecological neoplasms: ovary, cervix, and endometrium. 124
Staging of gynecologic malignancies 124
Clear cell degeneration associated with endometriosis of abdominal wall after cesarean section: A case report and systematic review of literature 124
Carcinoma of the cervix uteri. FIGO 6th Annual Report on the Results of Treatment in Gynecological Cancer. 122
Uterine sarcomas: a clinicopathologic study 122
Carcinoma of the ovary 122
Early non-compliance to ERAS in gynecological open surgery for malignancies, and post-operative complications: a multicenter, prospective, observational, cohort study 121
Carcinoma of the ovary 121
Optimizing gemcitabine regimens in ovarian cancer. 121
Carcinoma of the vagina 121
Revised FIGO staging for carcinoma of the cervix. 120
Recurrent ovarian carcinoma: salvage treatment with platinum in patients responding to first-line platinum-based regimens 120
Carcinoma of the cervix uteri 120
Pre-treatment Serum HE4 Level as a Novel Independent Prognostic Biomarker for Uterine Cervical Carcinoma Patients 120
Which second-line treatment regimen should be used following relapse of platinum-sensitive ovarian cancer? 119
Crossover study with cisplatin or carboplatin in advanced ovarian cancer 118
Ovarial cancer: best timing and applications of debulking surgery 118
Identical TP53 mutations in pelvic carcinosarcomas and associated serous tubal intraepithelial carcinomas provide evidence of their clonal relationship 118
Cancer in women 117
Real World Application of Chemotherapy Response Score in High Grade Serous Cancer of the Ovary 117
Integrated mutational landscape analysis of uterine leiomyosarcomas 115
Investigation of the ovarian and prostate cancer peptidome for candidate early detection markers using a novel nanoparticle biomarker capture technology. 114
Integrated Biomarker Analysis Reveals L1CAM as a Potential Stratification Marker for No Specific Molecular Profile High-Risk Endometrial Carcinoma 113
Prognostic role of immunohistochemical and molecular markers in no specific molecular profile endometrial cancer: a systematic review and meta-analysis 113
High-risk early-stage ovarian cancer. Randomized clinical trial comparing cisplatin plus cyclophosphamide versus whole abdominal radiotherapy 113
FXYD5 (Dysadherin) upregulation predicts shorter survival and reveals platinum resistance in high-grade serous ovarian cancer patients 112
Randomized study comparing chemotherapy plus radiotherapy versus radiotherapy alone in FIGO stage IIB-III cervical carcinoma. GONO (North-West Oncologic Cooperative Group) 111
Carcinoma of the vulva 111
Carcinoma of the vagina 111
Chronic hypertension in pregnancy: insights into adverse outcomes prevention 111
Effect of COVID-19 pandemic lockdowns on planned cancer surgery for 15 tumour types in 61 countries: an international, prospective, cohort study 109
Delaying surgery for patients with a previous SARS-CoV-2 infection 109
L1CAM expression as a predictor of platinum response in high-risk endometrial carcinoma 109
Totale 17.500
Salva come PNG Salva come JPEG
Categoria #
all - tutte 102.403
article - articoli 0
book - libri 0
conference - conferenze 0
curatela - curatele 0
other - altro 0
patent - brevetti 0
selected - selezionate 0
volume - volumi 0
Totale 102.403
Salva come PNG Salva come JPEG


Totale Lug Ago Sett Ott Nov Dic Gen Feb Mar Apr Mag Giu
2020/202176 0 0 0 0 0 0 0 0 0 0 0 76
2021/20221.018 64 157 6 43 3 51 105 70 48 122 96 253
2022/20232.139 159 59 207 274 229 283 67 148 193 128 211 181
2023/20242.370 177 106 201 159 209 375 137 183 361 245 45 172
2024/20253.546 42 113 96 471 307 310 324 143 392 252 657 439
2025/20267.287 683 832 447 826 728 471 1.085 348 423 629 457 358
Totale 23.170